Asahi Intecc (7747) Q1 2026 earnings summary

Executive summary

• Revenue/net sales grew 15.6% year-over-year to ¥36,058 million, driven by strong demand in both Medical and Device Divisions.

• Operating profit surged 34.0% year-over-year to ¥13,035 million, with gross profit margin improving to 70.5%.

• Net income attributable to parent company shareholders increased 35.7% year-over-year to ¥9,205 million.

• Comprehensive income jumped from ¥2,560 million to ¥11,795 million, reflecting favorable foreign currency translation adjustments.

• Ordinary profit rose 47.0% year-over-year to ¥12,887 million, aided by reduced foreign exchange losses.

Financial highlights

• Gross profit rose 18.1% year-over-year to ¥25,436 million, with margin up from 69.0% to 70.5%.

• EPS increased from ¥24.98 to ¥34.37, a 37.6% rise year-over-year.

• Total assets decreased from ¥193,187 million to ¥184,846 million, mainly due to lower cash and receivables.

• Net assets declined to ¥148,941 million, mainly due to treasury share purchases.

• SGA expenses increased 5.1% year-over-year, mainly due to higher sales and R&D expenses.

Outlook and guidance

• Full-year forecast for fiscal year ending June 30, 2026, remains unchanged: net sales of ¥130,870 million (+9.0% YoY), operating profit of ¥32,642 million (+8.5%), ordinary profit of ¥32,809 million (+11.0%), and profit attributable to owners of parent of ¥23,811 million (+86.9%).

• Dividend forecast for the year is ¥30.91 per share.

• Management notes that forward-looking statements are subject to risks and uncertainties, and actual results may differ significantly from forecasts.

• Uncertainties remain regarding sales trends, especially in Europe due to price revisions and front-loaded orders.